Biofrontera AG (FRA:B8FK)

Market Cap	16.10M +0.4%
Revenue (ttm)	13.63M +11.9%
Net Income	-2.44M
EPS	-0.40
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,372
Open	2.610
Previous Close	2.650
Day's Range	2.610 - 2.610
52-Week Range	2.010 - 2.850
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 31, 2026

About Biofrontera AG

Biofrontera AG, a biopharmaceutical company, engages in the research, development, and distribution of dermatological products and medical products in Germany, Spain, the United Kingdom, rest of Europe, the United States, and internationally. The company offers Ameluz and BF-RhodoLED lamp for the treatment of mild and moderate actinic keratoses on the face and scalp, field cancerization, and fatal squamous cell carcinoma. The company also provides RhodoLED XL lamp for the treatment of multiple interspersed lesions; and Belixos, a cosmetic produ...

• Industry: Pharmaceutical Preparations
• Founded: 1997
• Employees: 74
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: B8FK

Financial Performance

In 2025, Biofrontera AG's revenue was 13.19 million, an increase of 8.26% compared to the previous year's 12.18 million. Losses were -3.97 million, -8.85% less than in 2024.